• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

    3/13/25 6:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation's Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

    The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.

    Investors who wish to schedule a meeting with Revelation's management during the conference should contact their Roth representative.

    About Revelation Biosciences, Inc.

    Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

    For more information on Revelation, please visit www.RevBiosciences.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250313776522/en/

    Company Contacts

    Mike Porter

    Investor Relations

    Porter LeVay & Rose Inc.

    Email: [email protected]



    Chester Zygmont, III

    Chief Financial Officer

    Revelation Biosciences Inc.

    Email: [email protected]

    Get the next $REVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chawla Lakhmir S was granted 181 shares (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:14:40 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carver Jennifer was granted 181 shares, increasing direct ownership by 3,017% to 187 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:12:17 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roper Jess was granted 181 shares, increasing direct ownership by 9,050% to 183 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:09:20 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care